Source link : https://newshealth.biz/health-news/interim-data-support-elafibranor-in-rare-chronic-liver-disease/
(MedPage Today) — WASHINGTON — Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to interim results… Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118401 Author : Publish date : 2025-11-09 21:16:00 Copyright for syndicated content belongs to the linked […]
The post Interim Data Support Elafibranor in Rare Chronic Liver Disease first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-09 21:16:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8